

## Cell cycle regulation of the p34<sup>cdc2</sup>/p33<sup>cdk2</sup>-activating kinase p40<sup>MO15</sup>

Randy Y. C. Poon<sup>1</sup>, Katsumi Yamashita<sup>1</sup>, Michael Howell<sup>1</sup>, Maxim A. Ershler<sup>2</sup>, Alexander Belyavsky<sup>2</sup> and Tim Hunt<sup>1,\*</sup>

<sup>1</sup>Imperial Cancer Research Fund, Clare Hall Laboratories, South Mimms, Herts EN6 3LD, UK

<sup>2</sup>W. Engelhardt Institute of Molecular Biology, Russian Academy of Science, Vavilov Str. 32, Moscow B-334, Russia

\*Author for correspondence

### SUMMARY

A key component of Cdc2/Cdk2-activating kinase (CAK) is p40<sup>MO15</sup>, a protein kinase subunit that phosphorylates the T161/T160 residues of p34<sup>cdc2</sup>/p33<sup>cdk2</sup>. The level and activity of p40<sup>MO15</sup> were essentially constant during cleavage of fertilised *Xenopus* eggs and in growing mouse 3T3 cells, but serum starvation of these cells reduced both the level and activity of p40<sup>MO15</sup>. Although the level and activity of endogenous p40<sup>MO15</sup> did not vary in the cell cycle, we found that bacterially expressed p40<sup>MO15</sup> was activated more rapidly by M-phase cell extracts than by interphase cell extracts. Bacterially expressed p40<sup>MO15</sup> was

phosphorylated mainly on serine 170 (a p34<sup>cdc2</sup> phosphorylation site) by mitotic cell extracts, but mutation of S170 to alanine did not affect the activation of p40<sup>MO15</sup>, whereas mutation of T176 (the equivalent site to T161/T160 in p34<sup>cdc2</sup>/p33<sup>cdk2</sup>) abolished the activation of p40<sup>MO15</sup>. These studies suggest that the level and activity of p40<sup>MO15</sup> is probably not a major determinant of p34<sup>cdc2</sup>/p33<sup>cdk2</sup> activity in the cell cycle, and that the activation of p40<sup>MO15</sup> may require phosphorylation on T176.

Key words: CAK, cell cycle, cyclin-dependent kinase

### INTRODUCTION

Cyclins and cyclin-dependent kinases (CDKs) are key regulators of the eukaryotic cell cycle (reviewed by Norbury and Nurse, 1992). In higher eukaryotes, two CDKs appear to drive M-phase and G<sub>1</sub>/S-phase in conjunction with different cyclin subunits. Cyclin B and p34<sup>cdc2</sup> are components of maturation promoting factor (MPF) (Dunphy et al., 1988; Gautier et al., 1988), which plays an essential role in the entry to mitosis (Nurse, 1990). A closely related kinase subunit, p33<sup>cdk2</sup> (Elledge and Spottswood, 1991; Hirai et al., 1992; Ninomiya-Tsuji et al., 1991; Paris et al., 1991; Tsai et al., 1991), is thought to function earlier in the cell cycle than p34<sup>cdc2</sup> (Dulić et al., 1992; Koff et al., 1991; Koff et al., 1992; Lees et al., 1992). In mammalian cells, p33<sup>cdk2</sup> associates with cyclin E in G<sub>1</sub>-phase (Dulić et al., 1992; Koff et al., 1992) and cyclin A during S-phase (Rosenblatt et al., 1992). A role for p33<sup>cdk2</sup> has also been suggested in CSF-induced M-phase arrest (Gabrielli et al., 1993).

The activity of p34<sup>cdc2</sup> depends on association with a cyclin subunit but is also regulated by phosphorylation and dephosphorylation on p34<sup>cdc2</sup> (reviewed by Murray, 1993). Phosphorylation of residues T14 and Y15 of p34<sup>cdc2</sup> inhibit its activity, where the Wee1 protein kinase (Featherstone and Russell, 1991; Parker et al., 1992; Russell and Nurse, 1987) and Cdc25 tyrosine phosphatases (Dunphy and Kumagai, 1991; Gautier et al., 1991; Lee et al., 1992; Millar et al., 1991) have mutually antagonistic roles. p33<sup>cdk2</sup> may also be regulated in a similar manner to p34<sup>cdc2</sup> (Gabrielli et al., 1992; Gu et al., 1992; Sebastian et al., 1993). Conversely, phosphorylation of T161

is required for the activation of p34<sup>cdc2</sup> (Gould et al., 1991; Norbury et al., 1991; Solomon et al., 1992) as is the phosphorylation of T160 in p33<sup>cdk2</sup> (Gu et al., 1992; Poon et al., 1993). The T161/T160 is phosphorylated by a kinase termed p34<sup>cdc2</sup>/p33<sup>cdk2</sup>-activating kinase (CAK), and the CDK-related protein p40<sup>MO15</sup> was recently identified as the catalytic subunit of CAK (Fesquet et al., 1993; Poon et al., 1993; Solomon et al., 1993). Structural studies of p34<sup>cdc2</sup>/p33<sup>cdk2</sup> suggest that phosphorylation of T161/T160 may induce a change in the conformation of the T-loop and allow access of the substrate to ATP (De Bondt et al., 1993). It is clear that like other members of the cdc2 family of protein kinases, p40<sup>MO15</sup> requires additional protein subunits for activity, but at present their number and identity is not clear. In starfish, the active enzyme comprises two components (Fesquet et al., 1993), whereas there is recent evidence that human CAK may have three subunits (Tassan et al., 1994).

Given that p40<sup>MO15</sup> is a component of CAK, an important question is whether its activity is regulated during progression through the cell cycle, since p40<sup>MO15</sup> is necessary (albeit not sufficient) for the activation of both p34<sup>cdc2</sup> and p33<sup>cdk2</sup>. Any variation of p40<sup>MO15</sup> activity in the cell cycle could potentially play a role in the regulation of p34<sup>cdc2</sup>/p33<sup>cdk2</sup>. In this paper, we show that the level and activity of p40<sup>MO15</sup> in cell extracts are constant during the rapid cell cycles of embryonic cells and synchronised cultured cells, but both the level and activity of p40<sup>MO15</sup> are diminished when mouse Swiss 3T3K cells enter quiescent G<sub>0</sub>-phase as a result of serum deprivation; under these conditions, the levels of p34<sup>cdc2</sup>/p33<sup>cdk2</sup> and of most of the cyclins are reduced at least as much, if not more.

We demonstrated previously that a bacterially expressed glutathione S-transferase (GST)-MO15 fusion protein could be activated by 'marinating' it in crude cell extracts (Poon et al., 1993). Although the level and activity of endogenous p40<sup>MO15</sup> did not vary in the cell cycle, we found that GST-MO15 was more rapidly and completely activated by M-phase cell extracts than by cell extracts in interphase. GST-MO15 was phosphorylated on both serine and threonine by these extracts, and the rate of phosphorylation of GST-MO15 was higher in M-phase extracts than in interphase extracts. Mutation studies suggested that one of the serine phosphorylation sites in GST-MO15 is serine 170 (a p34<sup>cdc2</sup>/p33<sup>cdk2</sup> phosphorylation site), but mutation of S170 to alanine did not affect the activity of GST-MO15. By contrast, mutation of T176 to alanine completely inhibited the ability of GST-MO15 to acquire protein kinase activity.

## MATERIALS AND METHODS

### Plasmid constructs

Histidine-tagged Protein A-cyclin A (PA-cyclin A), GST-cdk2, GST-cdk2 K33R, GST-MO15 and GST-MO15 K47R constructs were described previously by Poon et al. (1993). The T176A, S170A and S186A mutants of GST-MO15 were constructed by a PCR method essentially as described by Horton and Pease (1991) with the following oligonucleotides and their antisense counterparts:

T176A, 5' CGTACTTACGCCCATGAGGTG 3';  
S170A, 5' AAGTCATTTGGGGCCCCAAACAGAATA 3';  
S186A, 5' TGGTACCGAGCTCCTGAGTTG 3'.

The mouse MO15 clone (whose sequence is listed under GenBank accession number X74145) described by Ershler et al. (1993) and Stepanova et al. (1994) was amplified by PCR with the following oligonucleotides: 5' CCTGGAGATTCAGATCTTGAT 3' and 5' CCTTTGGATCCTTTATTTTTCAG 3'. The amplified fragment was cut with *Bgl*III and *Bam*HI and ligated with *Bam*HI-cut pET16b vector. This construct expressed the C-terminal 130 residues of mouse MO15 with an N-terminal decahistidine 'tag' when induced with IPTG (isopropyl β-D-thiogalactopyranoside) in the bacterial host BL21(DE3). This polypeptide was used to raise an antiserum as described in the next section, and below in 'Antibodies and immunological methods'.

### Expression and purification of recombinant proteins from bacteria

PA-cyclin A was expressed in *Escherichia coli* and purified by NTA-Ni<sup>2+</sup> agarose (Qiagen) affinity chromatography as described previously (Poon et al., 1993) except that EDTA was omitted from the bacterial lysis buffer (see Poon and Hunt, 1994). Wild-type or mutant GST-MO15 and GST-cdk2 were expressed in *E. coli* and purified by affinity chromatography on GSH-Sepharose as described previously (Poon et al., 1993).

### Preparation of *Xenopus* egg extracts

*Xenopus* CSF-arrested extracts were prepared following the method of Murray (1991); 100 µg/ml of cycloheximide was added so that CSF-arrested extracts contained the same concentration of cycloheximide as interphase extracts. Interphase extracts were prepared by making CSF-arrested extracts 0.4 mM in CaCl<sub>2</sub> and 100 µg/ml cycloheximide, followed by incubation at 23°C for 20 minutes. Interphase extracts were subsequently 'activated' if required by addition of 100 µg/ml PA-cyclin A (1.42 µM) and incubation at 23°C for 20 minutes.

### *Xenopus* developmental samples

Freshly laid *Xenopus* eggs were fertilised in 0.5 mM HEPES, pH 7.8,

8.8 mM NaCl, 0.1 mM KCl, 0.07 mM CaCl<sub>2</sub>, 0.1 mM MgSO<sub>4</sub>, 0.25 mM NaHCO<sub>3</sub>. At different times after fertilisation, five embryos at the same stage were sampled and frozen in liquid nitrogen. Embryos were staged according to Nieuwkoop and Faber (1994). The samples were mixed with 300 µl of SDS-sample buffer and boiled. Insoluble material was removed by centrifugation for 5 minutes in a microfuge.

### Synchronisation of mouse Swiss 3T3K cells

Swiss 3T3K cells were grown in 15 cm plates in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) foetal calf serum in a humidified incubator at 37°C, in 5% CO<sub>2</sub> until the cultures reached about 50% confluence. The medium was then changed to DMEM with 0.2% (v/v) foetal calf serum for 48 hours. Cells were released from the G<sub>0</sub> arrest by supplying the cells with medium containing DMEM with 10% (v/v) foetal calf serum. Samples were taken at 3 hour intervals for 27 hours after 'refeeding'. At each time point, the cells were washed with phosphate buffered saline (137 mM NaCl, 3 mM KCl, 10 mM Na<sub>2</sub>HPO<sub>4</sub>, 2 mM KH<sub>2</sub>PO<sub>4</sub>) and scraped off the plates. One fifth of the sample was resuspended in 70% ethanol for later FACS (fluorescence-activated cell sorter) analysis. The rest of the cells were harvested by centrifugation and mixed with twice the pellet volume of a detergent lysis buffer containing 50 mM Tris-HCl, pH 7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 0.2% Nonidet P-40, 10 µg/ml cytochalasin B, 1 µg/ml leupeptin, 2 µg/ml aprotinin, 15 µg/ml benzamidine, 10 µg/ml chymostatin, 10 µg/ml pepstatin, 1 mM PMSF, 10 µg/ml soybean trypsin inhibitor. The suspension was incubated on ice for 30 minutes and cell debris removed by centrifugation in a microfuge at 4°C for 30 minutes. The protein concentration of the cell extract was measured with the Bradford dye method (Bradford, 1976).

### Histone H1 kinase assay

The histone H1 kinase activity of cell extracts was measured by mixing 1 µl of extract with 9 µl of kinase buffer (80 mM Na-β-glycerophosphate, pH 7.4, 20 mM EGTA, 15 mM Mg(OAc)<sub>2</sub> and 1 mM DTT) supplemented with 1 µg histone H1, 30 µM ATP and 1.25 µCi [<sup>32</sup>P]ATP followed by incubation at 23°C for 20 minutes. The reaction was terminated by addition of 25 µl of SDS-sample buffer and analysed by SDS-PAGE and autoradiography. For assaying immobilised samples, the beads were mixed with 10 µl of kinase buffer supplemented with 1 µg histone H1, 30 µM ATP and 1.25 µCi [<sup>32</sup>P]ATP, and then the same procedure as described above was followed.

### GST-cdk2 kinase assay

Immunoprecipitates of p40<sup>MO15</sup> or immobilised GST-MO15 were washed three times with 250 µl of bead buffer (50 mM Tris-HCl, pH 7.4, 5 mM NaF, 250 mM NaCl, 5 mM EDTA, 5 mM EGTA, 0.1% Nonidet P-40, 2 µg/ml aprotinin, 15 µg/ml benzamidine, 1 µg/ml leupeptin and 10 µg/ml soybean trypsin inhibitor) and twice with 250 µl of kinase buffer. The kinase activity towards GST-cdk2 was measured by adding 10 µl of kinase buffer containing 30 µM ATP, 5 µCi [<sup>32</sup>P]ATP and 100 µg/ml GST-cdk2 K33R. The reaction was carried out at 23°C for 30 minutes and terminated by addition of 25 µl of SDS-PAGE sample buffer. The samples were analysed by SDS-PAGE and autoradiography.

### Activation of GST-MO15 by cell extracts

*Xenopus* egg extract (10 µl) was incubated with 100 µg/ml of GST-MO15 (or mutants) at 23°C for 30 minutes. The sample was then mixed with 250 µl of bead buffer, and GST-MO15 was harvested with 10 µl of GSH-Sepharose with end-to-end rotation at 4°C for 30 minutes. The beads were washed three times with 250 µl of bead buffer and twice with kinase buffer. The protein kinase activity retained on the beads using GST-cdk2 K33R as substrate was then assayed as described above.

### Phosphorylation of GST-MO15 by cell extracts

*Xenopus* egg extract was diluted five-fold with kinase buffer, 0.5  $\mu\text{Ci}/\mu\text{l}$  [ $\gamma$ - $^{32}\text{P}$ ]ATP and 100  $\mu\text{g}/\text{ml}$  of GST-MO15 (or mutant variants thereof) were added, and the mixture incubated at 23°C for 60 minutes. The reaction was terminated by addition of 250  $\mu\text{l}$  of ice-cold bead buffer, and GST-MO15 was harvested with 10  $\mu\text{l}$  of GSH-Sepharose with end-to-end rotation at 4°C for 30 minutes. The beads were washed five times with 250  $\mu\text{l}$  of bead buffer. The GST-MO15 was eluted from the beads with 25  $\mu\text{l}$  of SDS-sample buffer and analysed by SDS-PAGE and autoradiography.

### Phosphoamino-acid analysis

One-dimensional phosphoamino-acid analysis after partial acid hydrolysis was performed on  $^{32}\text{PO}_4$ -labelled polypeptides after transfer to Immobilon (Millipore) as described by Kamps (1991). Polygram TLC plates (Macherey-Nagel) were used to separate phosphoamino acids by electrophoresis at 1000 V for 30 minutes with pH 3.5 buffer. Samples for analysis were mixed with phosphoserine, phosphothreonine and phosphotyrosine standards and stained with ninhydrin prior to autoradiography to determine their mobility.


### Antibodies and immunological methods

An anti-mouse p40<sup>MO15</sup> antiserum was raised in rabbits by subcutaneous injection of inclusion bodies of bacterially expressed mouse MO15 fragment (the C-terminal 130 amino acids). Rabbit anti-cyclin A antibody and anti-cyclin B1 antibody were raised against hamster cyclin A and cyclin B1, respectively (Tazunoki et al., unpublished data). These antibodies also recognise mouse cyclin A and cyclin B1, respectively. Rabbit anti-*Xenopus* p40<sup>MO15</sup> antiserum was raised against a synthetic peptide corresponding to the C-terminal 11 amino acids of *Xenopus* p40<sup>MO15</sup> (CADQKDI AKKLSF). Rabbit anti-GST antiserum was as described by Poon et al. (1993). Rabbit anti-human p33<sup>cdk2</sup> antiserum was raised against a synthetic peptide corresponding to the C-terminal 15 amino acid residues of human p33<sup>cdk2</sup> (PFFQDVTKPVPHLRL); this antiserum also recognises mouse p33<sup>cdk2</sup>. Rabbit anti-*Xenopus* p33<sup>cdk2</sup> antiserum was raised against bacterially expressed *Xenopus* p33<sup>cdk2</sup>. Anti-p34<sup>cdc2</sup> monoclonal antibody (A17) was raised against the C-terminal half of *Xenopus* p34<sup>cdc2</sup> as described by Kobayashi et al. (1991); this antibody also recognises mouse and human p34<sup>cdc2</sup>. Immunoblotting and immunoprecipitation were performed as described previously (Poon et al., 1993).

## RESULTS

### Cell cycle variation of p40<sup>MO15</sup> level and activity

To study the level and activity of p40<sup>MO15</sup> during *Xenopus* rapid cleavage cell cycles, *Xenopus* CSF-arrested extract (with high histone H1 kinase activity) was induced to enter interphase (with low histone H1 kinase activity) by addition of 0.4 mM CaCl<sub>2</sub>. Cycloheximide was added to prevent further cyclin synthesis, which would otherwise allow the extract eventually to return to M-phase spontaneously. The histone H1 kinase activity of the extract was returned to a high level by addition of 1.4  $\mu\text{M}$  Protein A-cyclin A (PA-cyclin A) protein (Fig. 1, top panel). The relative amount of p40<sup>MO15</sup> in the cell extracts was measured by immunoblotting with anti-p40<sup>MO15</sup> antibody (middle panel; note that the Protein A moiety on the cyclin A fusion protein reacts with the second antibody used for ECL detection). The CAK activity of p40<sup>MO15</sup> was measured by the ability of p40<sup>MO15</sup> immunoprecipitates to phosphorylate GST-cdk2 (bottom panel). Fig. 1 shows that both the level of p40<sup>MO15</sup> and its activity was the same in M-phase and interphase extracts.




**Fig. 1.** Cell cycle variation of p40<sup>MO15</sup> activity in *Xenopus* eggs. *Xenopus* CSF-arrested egg extract was made 0.4 mM in CaCl<sub>2</sub> and 100  $\mu\text{g}/\text{ml}$  cycloheximide and incubated at 23°C. After 30 minutes, 100  $\mu\text{g}/\text{ml}$  of PA-cyclin A was added. Samples were taken at the indicated time points and frozen in liquid N<sub>2</sub>. Each sample was divided into three portions, which were assayed for histone H1 kinase (top panel), immunoblotted with anti-p40<sup>MO15</sup> antibody (middle panel), and immunoprecipitated with anti-p40<sup>MO15</sup> antibody followed by GST-cdk2 kinase assay (lower panel).

*Xenopus* somatic cultured cells (WAK cells) can be blocked at the G<sub>1</sub>/S boundary with aphidicolin, and cells can be released synchronously into the cell cycle by removal of aphidicolin. No change in the level or activity of p40<sup>MO15</sup> was found in WAK cells after release from the aphidicolin block (data not shown).

To study p40<sup>MO15</sup> activity in somatic cell cycles in more detail, we raised an antiserum against the bacterially expressed C-terminal half of mouse p40<sup>MO15</sup> (Stepanova et al., 1994). The anti-mouse p40<sup>MO15</sup> antiserum recognised a 40 kDa protein in immunoblots of Swiss 3T3K cell extracts, but did not recognise the p40<sup>MO15</sup> from a similar amount of human HeLa cell extract or *Xenopus* WAK cell extract (Fig. 2A). Fig. 2B, lane 2, shows that the anti-mouse p40<sup>MO15</sup> antibody also immunoprecipitated GST-cdk2 kinase activity from Swiss 3T3K cell extract, whereas preimmune serum (lane 1) did not.

On serum starvation, the mouse cell line Swiss 3T3K (Todaro and Green, 1963) exit the cell cycle to a quiescent state (G<sub>0</sub>), and can be released from G<sub>0</sub> back into the cell cycle by addition of serum. Swiss 3T3K cells were arrested by growing in medium containing 0.2% (v/v) foetal calf serum for 48 hours and the cells were then released by supplying the cells with medium containing 10% foetal calf serum. Cells were sampled at 3 hour time points for FACS analysis and cell-free extracts. FACS analysis revealed that more than 85% of the cells had a 2C DNA content after serum starvation (Fig. 3A). The serum-stimulated cells started to enter S-phase about 15 hours after release from serum starvation, indicating that the cells had been arrested in G<sub>0</sub> rather than G<sub>1</sub>-phase. Almost



**Fig. 2.** Anti-mouse p40<sup>MO15</sup> antibody recognises p40<sup>MO15</sup> by immunoblotting and immunoprecipitation. (A) Equal amounts (15 µg) of cell extracts made from Swiss mouse 3T3K cells (lane 1), human HeLa cells (lane 2) and *Xenopus* WAK cells were immunoblotted with anti-mouse p40<sup>MO15</sup> antibody, and the immunoblot was developed with ECL system. (B) Swiss mouse 3T3K cell extract was immunoprecipitated with preimmune serum (lane 1) or anti-mouse p40<sup>MO15</sup> serum (lane 2). The GST-cdk2 kinase activity associated with the immunoprecipitates was assayed as described in Materials and Methods. The phosphorylated gel band of GST-cdk2 was detected with a phosphorimager (Molecular Dynamics).

all the cells were in S-phase 18 hours after serum release; they reached G<sub>2</sub>-phase at around 21 hours and completed M-phase by 24 hours.

The protein concentrations of the cell extracts were measured and adjusted to the same concentration with buffer. After immunoprecipitation with anti-p40<sup>MO15</sup> antiserum, the kinase activity of each sample was assayed using kinase-dead GST-cdk2 K33R as substrate. Fig. 3B shows that the CAK activity associated with p40<sup>MO15</sup> immunoprecipitates from G<sub>0</sub>-arrested cells was 10–15% of that in exponentially growing cells, and that the level of CAK activity increased gradually while the cells re-entered the cell cycle to G<sub>1</sub>-phase. The activity stayed relatively constant thereafter. Immunoblotting with anti-p40<sup>MO15</sup> antiserum (Fig. 3C) showed that the level of p40<sup>MO15</sup> was also reduced by about 90% in G<sub>0</sub> cells and increased after serum stimulation in parallel with the profile of p40<sup>MO15</sup> activity shown in Fig. 3J. The same samples were also immunoblotted with anti-p34<sup>cdc2</sup>, p33<sup>cdk2</sup>, cyclin A and cyclin B1 antibodies (Fig. 3D,E,F and G). The level of p33<sup>cdk2</sup> was reduced to about 25% of serum-replete cultures, whereas p34<sup>cdc2</sup> was undetectable in G<sub>0</sub> cells and did not begin to increase until 11 hours after serum stimulation. Cyclin A was first detectable at about 11 hours and cyclin B at 15 hours after serum stimulation, rising to a peak at 21 hours in late G<sub>2</sub>- to M-phase, with cyclin A rising 1–2 hours earlier than cyclin B. The levels of cyclin A and cyclin B were closely related to the histone H1 kinase activity associated with p33<sup>cdk2</sup> and p34<sup>cdc2</sup>, respectively (Fig. 3H and I). Fig. 3J top panel shows the quantitation of the GST-cdk2 kinase activity associated with p40<sup>MO15</sup>, and the histone H1 kinase activity associated with


p34<sup>cdc2</sup> and p33<sup>cdk2</sup> (from Fig. 3B,H and I). Fig. 3J middle and bottom panels shows the quantitation of the amount of p40<sup>MO15</sup>, p34<sup>cdc2</sup>, p33<sup>cdk2</sup>, cyclin A and cyclin B1 from Fig. 3C to G. It is noteworthy that the levels of p34<sup>cdc2</sup> and of cyclins A and B1 fell below the level of detection during serum starvation, whereas the levels of p40<sup>MO15</sup> and of p33<sup>cdk2</sup> were maintained at about 15% and 25% (respectively) of their levels in exponentially growing (and cycling) cells.

#### p40<sup>MO15</sup> during *Xenopus* early development


The levels of p40<sup>MO15</sup> during early development of *Xenopus* embryos were measured by immunoblotting samples of *Xenopus* embryos with anti-p40<sup>MO15</sup> antibody. Equal numbers of embryos were taken at different stages of development up to the tadpole stage with tails about 1 cm long, as indicated in Fig. 4. Immunoblotting with anti-p40<sup>MO15</sup> antibody revealed a low but detectable level of p40<sup>MO15</sup> that decreased slightly during the early rapid cell divisions, increased around gastrula stage and then stayed relatively constant up to the tadpole stage (Fig. 4, top panel). In comparison, the level of p34<sup>cdc2</sup> remained at a roughly constant level after a transient decline during the early rapid cell divisions (Fig. 4, middle panel). The level of p33<sup>cdk2</sup> was about one-tenth of that of p34<sup>cdc2</sup> in unfertilised eggs and its amount also decreased slightly during the early rapid cell divisions, then slowly increased after gastrula stage, becoming comparable with that of p34<sup>cdc2</sup> in swimming tadpoles (Fig. 4, bottom panel). The concentration of p34<sup>cdc2</sup> in egg extracts lies between 0.5 and 1 µM (E. Stewart, personal communication).

#### Bacterially expressed MO15 is more rapidly activated by M-phase cell extracts than by interphase cell extracts

As we reported previously, GST-MO15 fusion protein produced in bacteria was inactive as a protein kinase, but it acquired activity after incubation in *Xenopus* egg extract (Poon et al., 1993). We next compared the ability of M-phase or interphase extracts to activate GST-MO15. As shown in Fig. 1, the activity and the level of endogenous p40<sup>MO15</sup> did not vary between M-phase egg extracts and interphase egg extracts. We were therefore surprised to find that bacterially-expressed GST-MO15 was more strongly activated by M-phase frog egg extracts than by interphase egg extracts (Fig. 5A). GST-MO15 was added to CSF-arrested egg extract, interphase egg extract or interphase egg extract reactivated with PA-cyclin A. After incubation, the GST-MO15 was recovered by affinity chromatography on GSH-Sepharose and assayed for its kinase activity using kinase-dead GST-cdk2 as a substrate. GST-MO15 was less active as a GST-cdk2 kinase after incubation with interphase extract (lane 3) than with CSF-arrested extract (lane 2) or interphase extract treated with PA-cyclin A (lane 4). Fig. 5B shows that the rate of activation of GST-MO15 by the M-phase extract was at least 5-fold higher than the rate of activation in interphase extract. The reason for this difference remains to be explored further, but we speculate that either there is a higher concentration of (putative) p40<sup>MO15</sup> partner(s) in M-phase extracts, or that the level of p40<sup>MO15</sup>-activating protein kinase is higher in M-phase than in interphase extracts (see Discussion). This result prompted us to investigate whether GST-MO15 was phosphorylated by cell extracts.



**Fig. 3.** p40<sup>MO15</sup> in synchronised Swiss 3T3K cells. (A) Swiss 3T3K cells were synchronised by serum starvation as described in the text. About 5×10<sup>6</sup> cells were taken at the indicated time points, fixed in 70% ethanol and stained with propidium iodide prior to FACS analysis. The vertical axis indicates the relative frequency of cells and the horizontal axis indicates the DNA content of the cells at the indicated time points after serum starvation. (B) Cell extracts were made from cells sampled at the indicated times and adjusted to the same protein concentration. The cell extracts were immunoprecipitated with anti-p40<sup>MO15</sup> antibody and the GST-cdk2 kinase activity was assayed. The cell extracts were dissolved in SDS-sample buffer and immunoblotted with (C) anti-p40<sup>MO15</sup> antibody; (D) anti-p34<sup>cdc2</sup> antibody (A17); (E) anti-p33<sup>cdk2</sup> antibody; (F) anti-cyclin A antibody (E23); and (G) anti-cyclin B1 antibody (from the same immunoblot after probing for cyclin A, without stripping the anti-cyclin A antibody). The histone H1 kinase activity associated with (H) p34<sup>cdc2</sup> and (I) p33<sup>cdk2</sup> immunoprecipitates were assayed as described in Materials and Methods. (J) Quantitation of the GST-cdk2 kinase activity associated with p40<sup>MO15</sup> and the histone H1 kinase activity associated with p34<sup>cdc2</sup> and p33<sup>cdk2</sup> (top panel), the amount of p40<sup>MO15</sup>, p34<sup>cdc2</sup>, p33<sup>cdk2</sup> (middle panel), cyclin A and cyclin B1 (bottom panel).



**Fig. 4.** The level of p40<sup>MO15</sup> during early development of *Xenopus laevis*. Selected stages of frog embryo development are shown at the bottom. The samples (15  $\mu$ l, equivalent to 0.25 of an embryo) were subjected to SDS-PAGE and immunoblotting. The embryos were at the stage of 2 cells (lane 1), 4 cells (lane 2), 8 cells (lane 3), 16 cells (lane 4), 4 hours post-fertilisation (pf) (lane 5), 5 hours pf (lane 6), 6 hours pf (lane 7), 6.5 hours pf (lane 8), 7 hours pf (lane 9), 7.5 hours pf (lane 10) (mid blastula), 8 hours pf (lane 11), 9 hours pf (lane 12), 10 hours pf (lane 13), 11.5 hours pf (lane 14) (early gastrula), 12 hours pf (lane 15) (mid gastrula), 14 hours pf (lane 16), 19.5 hours pf (lane 17) (late gastrula), 21 hours pf (lane 18) (early neurula), 23 hours pf (lane 19) (mid neurula), 26 hours pf (lane 20) (late neurula), 36 hours pf (lane 21) (hatch), 48 hours pf (lane 22) (early tailed), tail 1-1.5 mm (lane 23), tail <5 mm (lane 24), tail >5 mm (lane 25), tail 1 cm (lane 26). The samples were immunoblotted with anti-p40<sup>MO15</sup> antibody (top panel), affinity-purified anti-p33<sup>cdk2</sup> antiserum (middle panel), or anti-p34<sup>cdc2</sup> antibody A17 (bottom panel).


#### Phosphorylation of p40<sup>MO15</sup> by cell extracts

When phosphorylation reactions in a *Xenopus* egg extract were inhibited by addition of EDTA to chelate Mg<sup>2+</sup> and other divalent metal ions, the activation of GST-MO15 as a kinase for GST-cdk2 was completely inhibited (Fig. 6A, lane 4). A kinase-inactive mutant of GST-MO15 with the lysine in the ATP-binding region mutated to arginine (K47R) cannot be activated by cell extracts (lanes 5 and 6). The ATP-dependence of the activation, and the analogy with the activation of p33<sup>cdk2</sup> and p34<sup>cdc2</sup> suggested that phosphorylation was involved in the activation of GST-MO15.

We tested whether GST-MO15 was phosphorylated by cell extracts by mixing GST-MO15 K47R (which is incapable of self-phosphorylation) and [ $\gamma$ -<sup>32</sup>P]ATP with *Xenopus* egg

extract. After incubation, the GST-MO15 K47R was recovered with glutathione (GSH)-Sepharose and its phosphorylation was detected using SDS-PAGE and autoradiography. Under these conditions, GST-MO15 K47R was phosphorylated (Fig. 6B, lane 1) Phosphoamino-acid analysis of the phosphorylated band revealed mainly phosphoserine, although some phosphorylation on threonine was detectable, particularly if okadaic acid was present to inhibit protein phosphatase activity (lane 2). Digestion with thrombin revealed that the phosphorylation of GST-MO15 was on the MO15 domain and not on the GST domain (data not shown).

To test whether there was any cell cycle variation in the rate of phosphorylation of p40<sup>MO15</sup>, GST-MO15 was incubated with *Xenopus* CSF-arrested egg extract, interphase egg extract




**Fig. 5.** Activation of GST-MO15 by cell extracts at M-phase and interphase. (A) Buffer (lane 1), *Xenopus* CSF-arrested egg extract (lane 2), interphase egg extract (lane 3), or interphase egg extract treated with PA-cyclin A protein (lane 4) were incubated with GST-MO15 as described in Materials and Methods. GST-MO15 was then harvested with GSH-Sepharose and assayed for its GST-ckd2 kinase activity (lower panel). The upper panel shows the quantitation of the lower panel. (B) CSF-arrested egg extract (lanes 1-5) or interphase egg extract (lanes 6-10) were incubated with GST-MO15 as described in Materials and Methods. GST-MO15 was harvested at the indicated time points and assayed for its GST-ckd2 kinase activity (lower panel). The upper panel shows the quantitation of the lower panel.

or interphase egg extract treated with PA-cyclin A. As expected, the histone H1 kinase activity was at a high level in CSF-arrested egg extract and cyclin A-treated egg extract, but at a much reduced level in interphase extract (Fig. 6C, top panel). Phosphorylation of GST-MO15 (Fig. 6C, middle panel) was likewise higher in CSF-arrested egg extract (lane 1) than in interphase egg extract (lane 2), and the level of phosphorylation was very significantly elevated in interphase extract treated with cyclin A (lane 3).

Given that the GST-MO15 was phosphorylated mainly on serine residues, and the phosphorylation was higher when the kinase activity of p34<sup>cdc2</sup>/p33<sup>cdk2</sup> was activated (in CSF-arrested extract and PA-cyclin A-treated extract), it was possible that GST-MO15 was directly phosphorylated by p34<sup>cdc2</sup>/p33<sup>cdk2</sup>. The cyclin-dependent kinases p34<sup>cdc2</sup> and p33<sup>cdk2</sup> have a relatively rigid phosphorylation site specificity of a serine or threonine residue followed by a proline. *Xenopus* p40<sup>MO15</sup> contains two putative serine phosphorylation sites for p34<sup>cdc2</sup>/p33<sup>cdk2</sup> at S170 and S186. Among p40<sup>MO15</sup> from *Xenopus*, goldfish, mouse and human, S170 is present in all four species, but S186 is only present in *Xenopus*. Two mutants of *Xenopus* GST-MO15 were therefore constructed, with S170 or S186 changed to non-phosphorylatable alanine residues (S170A and S186A, respectively). These mutants, together with GST-MO15, GST-MO15 K47R, and GST-MO15 T176A (T176 is the equivalent residue to T160 in p33<sup>cdk2</sup>) were tested

for their ability to be phosphorylated in *Xenopus* egg extract (Fig. 7A). Wild-type GST-MO15, K47R and T176A mutants were all phosphorylated by egg extract to similar extents (top panel, lanes 2-4), the phosphorylation was predominantly on serine and only weakly on threonine (bottom panel). But GST-MO15 S170A was phosphorylated significantly less than the other GST-MO15 proteins (lane 5), although immunoblotting confirmed that a similar amount of protein was present in the reactions (middle panel). Phosphoamino-acid analysis revealed that most (but not all) serine phosphorylation seen in GST-MO15 was removed in the S170A mutant, whereas the threonine phosphorylation was not affected. No significant effect on the phosphorylation of GST-MO15 was detected with the S186A mutant (lane 6). We also found that GST-MO15 could be phosphorylated by cyclin B:p34<sup>cdc2</sup>-immunoprecipitates in vitro, and that mutation of S170A abolished most of this phosphorylation (data not shown). More surprisingly, however, mutation of T176 to alanine did not abolish the phosphothreonine labelling in this procedure.

To test whether any of the mutations of GST-MO15 shown above affected their CAK activity, GST-MO15 and its mutants were incubated with cell extracts, harvested with GSH-Sepharose and assayed for their kinase activities using GST-ckd2 as a substrate. Fig. 7B shows that the K47R and T176A mutations abolished the GST-ckd2 kinase activity of GST-MO15 (lanes 2-4). Longer exposure of the autoradiograph



**Fig. 6.** Phosphorylation of GST-MO15 by cell extracts. (A) *Xenopus* CSF-arrested egg extracts were incubated with buffer (lanes 1 and 2), GST-MO15 (lanes 3 and 4) or GST-MO15 K47R (lanes 5 and 6), in the absence (odd numbered lanes) or presence (even numbered lanes) of 10 mM EDTA. After 30 minutes at 23°C, the GST-MO15 and K47R mutant were harvested with GSH-Sepharose and assayed for their GST-cdk2 K33R kinase activity as described in Materials and Methods. The samples were applied to SDS-PAGE and phosphorylations were detected by autoradiography. (B) *Xenopus* CSF-arrested extract was mixed with [ $\gamma$ - $^{32}$ P]ATP and incubated with GST-MO15 K47R in the absence (lane 1) or presence (lane 2) of 1  $\mu$ M okadaic acid as described in Materials and Methods. The GST-MO15 K47R was then recovered with GSH-Sepharose and eluted with SDS-sample buffer. The samples were analysed with SDS-PAGE and autoradiography (top panel). The corresponding lanes were immunoblotted with anti-GST antibody (middle panel). One dimensional phosphoamino-acid analysis was performed on the radioactively labelled GST-MO15 K47R bands (bottom panel). The positions of internal marker phosphoserine (pS), phosphothreonine (pT) and phosphotyrosine (pY) are indicated. (C) *Xenopus* CSF-arrested egg extract (lane 1), interphase egg extract (lane 2), or interphase egg extract treated with PA-cyclin A protein (lane 3) were mixed with GST-MO15 K47R in the presence of [ $\gamma$ - $^{32}$ P]ATP as described in Materials and Methods. GST-MO15 K47R was then recovered with GSH-Sepharose and phosphorylation was detected with SDS-PAGE and autoradiography (middle panel). The corresponding samples were immunoblotted with anti-GST antibody to detect the harvested GST-MO15 K47R (bottom panel). The total histone H1 kinase activities of the egg extracts were assayed and subjected to SDS-PAGE and autoradiography (top panel).


showed that the T176A mutant retained very low GST-cdk2 kinase activity, whereas no such activity was detectable with the K47R mutant. This is reminiscent of the properties of p33<sup>cdk2</sup>, which retains about 1% of its kinase activity when T160 is changed to alanine (Connell-Crowley et al., 1993). By contrast, the GST-cdk2 kinase activities of the S170A and S186A mutants were essentially the same as that of wild-type GST-MO15 (Fig. 7B, lanes 5 and 6). Thus, although S170 is clearly phosphorylated by cell extracts containing active p34<sup>cdc2</sup>/p33<sup>cdk2</sup> kinase, mutation of S170 to alanine does not significantly affect the kinase activity of GST-MO15, and the rate of activation of the S170A construct in mitotic extracts

was essentially the same as that of the wild-type construct (data not shown).

## DISCUSSION

### Cell cycle variation of p40<sup>MO15</sup> activity

We show in this paper that there is no substantial variation on the level or kinase activity of p40<sup>MO15</sup> (CAK) during progress through either embryonic or somatic cell cycles. Similar conclusions have been reached by Tassan et al. (1994). Only when cells are induced to exit the cell cycle to a G<sub>0</sub> state by serum deprivation do the level and the kinase activity of p40<sup>MO15</sup>



**Fig. 7.** Phosphorylation and activation of GST-MO15 mutants. (A) *Xenopus* CSF-arrested extract was mixed with [ $\gamma$ - $^{32}$ P]ATP and incubated with buffer (lane 1), 100  $\mu$ g/ml of GST-MO15 (lane 2), K47R mutant (lane 3), T176A mutant (lane 4), S170A mutant (lane 5) or S186A mutant (lane 6) as described in Materials and Methods. The GST-MO15 or mutants were then recovered with GSH-Sepharose and dissolved in SDS-sample buffer. The samples were analysed with SDS-PAGE and autoradiography (top panel). The corresponding samples were immunoblotted with anti-GST antibody (middle panel). The corresponding radioactively labelled GST-MO15 or mutants bands were subjected to one-dimensional phosphoamino-acid analysis (bottom panel). The positions of internal marker phosphoserine (pS), phosphothreonine (pT) and phosphotyrosine (pY) are indicated. (B) *Xenopus* CSF-arrested egg extract was incubated with buffer (lane 1), 100  $\mu$ g/ml of GST-MO15 (lane 2), GST-MO15 K47R mutant (lane 3), T176A mutant (lane 4), S170A mutant (lane 5) or S186A mutant (lane 6). After 60 minutes at 23°C, the GST-MO15 and mutants were harvested with GSH-Sepharose and assayed for their kinase activity towards GST-cdk2 K33R as described in Materials and Methods (upper panel). The corresponding samples were immunoblotted with anti-GST antibody (lower panel).

become diminished. It is unlikely that the decrease in activity of p40<sup>MO15</sup> in G<sub>0</sub> is important in reducing the activity of either p34<sup>cdc2</sup> or p33<sup>cdk2</sup>, however, since the levels of both kinase subunits are themselves reduced by serum starvation. More critically, there was no detectable cyclin A nor cyclin B in extracts of serum-starved cells, and the lack of histone H1 kinase activity associated with p34<sup>cdc2</sup> and p33<sup>cdk2</sup> in G<sub>0</sub> can readily be ascribed to the combined lack of p34<sup>cdc2</sup>, p33<sup>cdk2</sup> and cyclins, rather than of p40<sup>MO15</sup>. These results do not exclude the possibility that p40<sup>MO15</sup> might be regulated in the cell cycle by other means, such as subcellular compartmentation. It is also possible that the p40<sup>MO15</sup> activity varies in the normal cell cycle in a way that our assay fails to register, and this variation might be sufficient to affect the activity of CDKs. It is also possible that the activity of p40<sup>MO15</sup> towards substrates other than p34<sup>cdc2</sup>/p33<sup>cdk2</sup> may vary in the cell cycle, although at present, no such substrates have been identified.

### Phosphorylation regulation of p40<sup>MO15</sup>

As discussed above, the activation of GST-MO15 by cell extracts is suspected to involve binding of GST-MO15 to a partner and phosphorylation of GST-MO15. Here we show that GST-MO15 is phosphorylated by cell extracts on serine and threonine residues. One phosphorylation site is likely to be S170, but mutation of S170 to alanine did not impair the activity of GST-MO15. On the other hand, mutation of T176 to alanine strongly inhibited GST-MO15 activation by cell extracts. Therefore, it is likely, although not rigorously proven that, as in the activation of p34<sup>cdc2</sup>, phosphorylation of T176

of p40<sup>MO15</sup> is necessary for its activity. It will be very interesting to learn what kinase is responsible for the phosphorylation of T176.

Mutation of T176 to alanine (T176A) did not affect the extent of GST-MO15 phosphorylated by cell extracts (Fig. 7A). Moreover, T176A mutant did not appear to reduce the small amount of threonine phosphorylation detected in GST-MO15, indicating that T176 is only a minor phosphorylation site under these conditions, though the lack of activity of the T176A mutant indicates that T176 is important for the activity of GST-MO15 (Fig. 7B). We suspect that T176 is phosphorylated in the active form of GST-MO15, and that the apparent weak phosphorylation detectable on T176 may be due to the fact that GST-MO15 may need to bind to a partner(s) in the cell extract before it can be phosphorylated on T176, and the partner(s) available for GST-MO15 may be limited in the cell extracts we used. On the other hand, phosphorylation of residues like S170 may not require association with partner(s) and is therefore much stronger. We suspect that only a small fraction of the added bacterially-produced GST-MO15 is converted to the enzymically active form.

Phosphorylation of S170 may be important in the regulation of p40<sup>MO15</sup> activity because it can be phosphorylated by active p34<sup>cdc2</sup>/p33<sup>cdk2</sup> in vitro (unpublished data), which are themselves activated by p40<sup>MO15</sup>. Hence, there could be some kind of feedback control. Furthermore, because S170 is close to the putative activating phosphorylation site of p40<sup>MO15</sup> (T176), phosphorylation of S170 may affect the conformation of T176. Although the S170A mutation does not affect the activation of

GST-MO15 in our assays, it is possible that S170 phosphorylation has an effect on the activity of p40<sup>MO15</sup> that was not detectable in the in vitro assay we used. Furthermore, S170 phosphorylation might be required for other processes, like nuclear localisation (Tassan et al., 1994), which we did not explore.

The result that GST-MO15 is activated more rapidly and completely by M-phase extract than by interphase extract (Fig. 5) is peculiar, since the activity of the endogenous p40<sup>MO15</sup> does not vary in these cell extracts (Fig. 1). One possibility suggested by this result is that the activating kinase for p40<sup>MO15</sup> (possibly for T176) may be more active in M-phase, in which case the endogenous p40<sup>MO15</sup> would not be affected because it is already phosphorylated (assuming the turnover of phosphorylated T176 is slow). Alternatively, the activity of the phosphatase for T176 of p40<sup>MO15</sup> may be lower in M-phase extracts than in interphase extracts. Another possibility is that there are more putative partner subunits available for GST-MO15 in M-phase extracts than in interphase extracts, or that their rates of exchange differ in M-phase and interphase extracts. Finally, it may be that the bacterially-expressed GST-MO15 requires significant refolding by chaperone-like proteins after it has been added to the extracts, and that the activity of these entities is different under different conditions. We cannot easily distinguish between these possibilities until the partner subunit(s) of p40<sup>MO15</sup> have been identified, which would allow the design and execution of more precisely focused biochemical assays.

We are grateful for the excellent technical support provided by the ICRF support services, in particular the animal unit, cell production unit, FACS unit, hybridoma unit, oligonucleotide unit and peptide synthesis unit. We thank Erich Nigg and John Shuttleworth for discussions and communicating results prior to publication.

## REFERENCES

- Bradford, M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* **72**, 248-254.
- Connell-Crowley, L., Solomon, M. J., Wei, N. and Harper, J. W. (1993). Phosphorylation independent activation of human cyclin-dependent kinase 2 by cyclin A in vitro. *Mol. Biol. Cell* **4**, 79-92.
- De Bondt, H. L., Rosenblatt, J., Jancarik, J., Jones, H. D., Morgan, D. O. and Kim, S.-H. (1993). Crystal structure of cyclin-dependent kinase 2. *Nature* **363**, 595-602.
- Dulić, V., Lees, E. and Reed, S. I. (1992). Association of human cyclin E with a periodic G<sub>1</sub>-S phase protein kinase. *Science* **257**, 1958-1961.
- Dunphy, W. G., Brizuela, L., Beach, D. and Newport, J. (1988). The *Xenopus* cdc2 protein is a component of MPF, a cytoplasmic regulator of mitosis. *Cell* **54**, 423-431.
- Dunphy, W. G. and Kumagai, A. (1991). The cdc25 protein contains an intrinsic phosphatase activity. *Cell* **67**, 189-196.
- Elledge, S. J. and Spottswood, M. R. (1991). A new human p34 protein kinase, CDK2, identified by complementation of a *cdc28* mutation in *Saccharomyces cerevisiae*, is a homolog of *Xenopus* Eg1. *EMBO J.* **10**, 2653-2660.
- Ershler, M. A., Nagorskaya, T. V., Visser, J. W. M. and Belyavsky, A. V. (1993). Novel CDC2-related protein kinases produced in murine hematopoietic stem cells. *Gene* **124**, 305-306.
- Featherstone, C. and Russell, P. (1991). Fission yeast p107<sup>wee1</sup> mitotic inhibitor is a tyrosine/serine kinase. *Nature* **349**, 808-811.
- Fesquet, D., Labbé, J.-C., Derancourt, J., Capony, J.-P., Galas, S., Girard, F., Lorca, T., Shuttleworth, J., Dorée, M. and Cavadore, J.-C. (1993). The MO15 gene encodes the catalytic subunit of a protein kinase that activates cdc2 and other cyclin-dependent kinases (CDKs) through phosphorylation of T161 and its homologues. *EMBO J.* **12**, 3111-3121.
- Gabrielli, B. G., Lee, M. S., Walker, D. H., Piwnica-Worms, H. and Maller, J. L. (1992). Cdc25 regulates the phosphorylation and activity of the *Xenopus* cdk2 protein kinase complex. *J. Biol. Chem.* **267**, 18040-18046.
- Gabrielli, B. G., Roy, L. M. and Maller, J. L. (1993). Requirement for cdk2 in cytostatic factor-mediated metaphase II arrest. *Science* **259**, 1766-1769.
- Gautier, J., Norbury, C., Lohka, M., Nurse, P. and Maller, J. (1988). Purified maturation-promoting factor contains the product of a *Xenopus* homolog of the fission yeast cell cycle control gene *cdc2*<sup>+</sup>. *Cell* **54**, 433-439.
- Gautier, J., Solomon, M. J., Booher, R. N., Bazan, J. F. and Kirschner, M. W. (1991). cdc25 is a specific tyrosine phosphatase that directly activates p34<sup>cdc2</sup>. *Cell* **67**, 197-211.
- Gould, K. L., Moreno, S., Owen, D. J., Sazer, S. and Nurse, P. (1991). Phosphorylation at Thr167 is required for *Schizosaccharomyces pombe* p34<sup>cdc2</sup> function. *EMBO J.* **10**, 3297-3309.
- Gu, Y., Rosenblatt, J. and Morgan, D. O. (1992). Cell cycle regulation of CDK2 activity by phosphorylation of threonine 160 and tyrosine 15. *EMBO J.* **11**, 3995-4005.
- Hirai, T., Yamashita, M., Yoshikuni, M., Tokumoto, T., Kajiura, H., Sakai, N. and Nagahama, Y. (1992). Isolation and characterization of goldfish cdk2, a cognate variant of the cell-cycle regulator cdc2. *Dev. Biol.* **152**, 113-120.
- Horton, R. M. and Pease, L. R. (1991). Recombination and mutagenesis of DNA sequences using PCR. In *Directed Mutagenesis* (ed. M. J. McPherson), pp. 217-247. Oxford: IRL Press at OUP.
- Kamps, M. P. (1991). Determination of phosphoamino acid composition by acid hydrolysis of protein blotted to immobilon. *Meth. Enzymol.* **201**, 21-27.
- Kobayashi, H., Golsteyn, R., Poon, R., Stewart, E., Gannon, J., Minshull, J., Smith, R. and Hunt, T. (1991). Cyclins and their partners during *Xenopus* oocyte maturation. *Cold Spring Harbor Symp. Quant. Biol.* **56**, 437-447.
- Koff, A., Cross, F., Fisher, A., Schumacher, J., Leguellec, K., Philippe, M. and Roberts, J. M. (1991). Human cyclin E, a new cyclin that interacts with two members of the cdc2 gene family. *Cell* **66**, 1217-1228.
- Koff, A., Giordano, A., Desai, D., Yamashita, K., Harper, J. W., Elledge, S., Nishimoto, T., Morgan, D. O., Franza, B. R. and Roberts, J. M. (1992). Formation and activation of a cyclin E-cdk2 complex during the G<sub>1</sub> phase of the human cycle. *Science* **257**, 1689-1694.
- Lee, M. S., Ogg, S., Xu, M., Parker, L. L., Donoghue, D. J., Maller, J. L. and Piwnica-Worms, H. (1992). cdc25<sup>+</sup> encodes a protein phosphatase that dephosphorylates p34<sup>cdc2</sup>. *Mol. Biol. Cell* **3**, 73-84.
- Lees, E., Fahs, B., Dulić, V., Reed, S. I. and Harlow, E. (1992). Cyclin E cdk2 and cyclin A cdk2 kinases associate with p107 and E2F in a temporally distinct manner. *Genes Dev.* **6**, 1874-1885.
- Millar, J. B. A., McGowan, C. H., Lenaers, G., Jones, R. and Russell, P. (1991). p80<sup>cdc25</sup> mitotic inducer is the tyrosine phosphatase that activates p34<sup>cdc2</sup> kinase in fission yeast. *EMBO J.* **10**, 4301-4309.
- Murray, A. W. (1991). Cell cycle extracts. In *Xenopus laevis: Practical Uses in Cell and Molecular Biology*. *Meth. Cell Biol.* **36**, 573-597.
- Murray, A. W. (1993). Turning on mitosis. *Current Biol.* **3**, 291-293.
- Nieuwkoop, P. D. and Faber, J. (eds) (1994). *Normal Table of Xenopus laevis* (Dudin), 3rd edn. Garland Publishing, Inc., New York, London.
- Ninomiya-Tsuji, J., Nomoto, S., Yasuda, H., Reed, S. I. and Matsumoto, K. (1991). Cloning of a human cDNA encoding a CDC2-related kinase by complementation of a budding yeast *cdc28* mutation. *Proc. Nat. Acad. Sci. USA* **88**, 9006-9010.
- Norbury, C., Blow, J. and Nurse, P. (1991). Regulatory phosphorylation of the p34<sup>cdc2</sup> protein kinase in vertebrates. *EMBO J.* **10**, 3321-3329.
- Norbury, C. and Nurse, P. (1992). Animal cell cycles and their control. *Annu. Rev. Biochem.* **61**, 441-470.
- Nurse, P. (1990). Universal control mechanism regulating cell cycle timing of M-phase. *Nature* **344**, 503-508.
- Paris, J., Le Guellec, R., Couturier, A., Le Guellec, K., Omilli, F., Camonis, J., MacNeill, S. and Philippe, M. (1991). Cloning by differential screening of a *Xenopus* cDNA coding for a protein highly homologous to cdc2. *Proc. Nat. Acad. Sci. USA* **88**, 1039-1043.
- Parker, L. L., Atherton-Fessler, S. and Piwnica Worms, H. (1992). P107<sup>(wee1)</sup> is a dual-specificity kinase that phosphorylates-p34<sup>(cdc2)</sup> on tyrosine-15. *Proc. Nat. Acad. Sci. USA* **89**, 2917-2921.
- Poon, R. Y. C., Yamashita, K., Adamczewski, J. P., Hunt, T. and Shuttleworth, J. (1993). The cdc2-related protein p40<sup>MO15</sup> is the catalytic subunit of a protein kinase that can activate p33<sup>cdk2</sup> and p34<sup>cdc2</sup>. *EMBO J.* **12**, 3123-3132.
- Poon, R. Y. C. and Hunt, T. (1994). Reversible immunoprecipitation using histidine- or glutathione S-transferase-tagged Staphylococcal Protein A. *Anal. Biochem.* **218**, 26-33.
- Rosenblatt, J., Gu, Y. and Morgan, D. O. (1992). Human cyclin-dependent

- kinase 2 is activated during the S and G<sub>2</sub> phases of the cell cycle and associates with cyclin A. *Proc. Nat. Acad. Sci. USA* **89**, 2824-2828.
- Russell, P. and Nurse, P.** (1987). Negative regulation of mitosis by *wee1+*, a gene encoding a protein kinase homolog. *Cell* **49**, 559-567.
- Sebastian, B., Kakizuka, A. and Hunter, T.** (1993). Cdc25M2 activation of cyclin-dependent kinases by dephosphorylation of threonine-14 and tyrosine-15. *Proc. Nat. Acad. Sci. USA* **90**, 3521-3524.
- Solomon, M. J., Lee, T. and Kirshner, M. W.** (1992). Role of phosphorylation in p34<sup>cdc2</sup> activation: identification of an activating kinase. *Mol. Biol. Cell* **3**, 13-27.
- Solomon, M. J., Harper, J. W. and Shuttleworth, J.** (1993). CAK, the p34<sup>cdc2</sup> activating kinase, contains a protein identical or closely related to p40<sup>MO15</sup>. *EMBO J.* **12**, 3133-3142.
- Stepanova, L. Y., Erschler, M. A. and Belyavsky, A. V.** (1994). Sequence of the cDNA encoding murine CRK4 protein kinase. *Gene* (in press).
- Tassan, J.-P., Schultzl, S. J., Bartek, J. and Nigg, E. A.** (1994). Cell cycle analysis of the activity, subcellular localization and subunit composition of human CAK (CDK-activating kinase). *J. Cell Biol.* (in press).
- Todaro, G. and Green, H.** (1963). Quantitative studies on the growth of mouse embryo cells in culture and their development into established lines. *J. Cell Biol.* **17**, 299-313.
- Tsai, L.-H., Harlow, E. and Meyerson, M.** (1991). Isolation of the human *cdk2* gene that encodes the cyclin A- and adenovirus E1A-associated p33 kinase. *Nature* **353**, 174-177.

(Received 11 May 1994 - Accepted 10 June 1994)